Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

487 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Major response to everolimus in melanoma with acquired imatinib resistance.
Si L, Xu X, Kong Y, Flaherty KT, Chi Z, Cui C, Sheng X, Li S, Dai J, Yu W, Guo J. Si L, et al. Among authors: flaherty kt. J Clin Oncol. 2012 Feb 1;30(4):e37-40. doi: 10.1200/JCO.2011.37.9644. Epub 2011 Dec 12. J Clin Oncol. 2012. PMID: 22162580 No abstract available.
Large-scale analysis of KIT aberrations in Chinese patients with melanoma.
Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lu A, Guo J. Kong Y, et al. Among authors: flaherty kt. Clin Cancer Res. 2011 Apr 1;17(7):1684-91. doi: 10.1158/1078-0432.CCR-10-2346. Epub 2011 Feb 15. Clin Cancer Res. 2011. PMID: 21325067
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S. Guo J, et al. Among authors: flaherty kt. J Clin Oncol. 2011 Jul 20;29(21):2904-9. doi: 10.1200/JCO.2010.33.9275. Epub 2011 Jun 20. J Clin Oncol. 2011. PMID: 21690468 Clinical Trial.
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A. Trunzer K, et al. Among authors: flaherty kt. J Clin Oncol. 2013 May 10;31(14):1767-74. doi: 10.1200/JCO.2012.44.7888. Epub 2013 Apr 8. J Clin Oncol. 2013. PMID: 23569304 Clinical Trial.
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Hodi FS, et al. Among authors: flaherty kt. J Clin Oncol. 2013 Sep 10;31(26):3182-90. doi: 10.1200/JCO.2012.47.7836. Epub 2013 Jun 17. J Clin Oncol. 2013. PMID: 23775962 Free PMC article. Clinical Trial.
Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.
O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli TC, Indig FE, Flaherty KT, Wargo JA, Frederick DT, Cooper ZA, Nair S, Amaravadi RK, Schuchter LM, Karakousis GC, Xu W, Xu X, Weeraratna AT. O'Connell MP, et al. Among authors: flaherty kt. Cancer Discov. 2013 Dec;3(12):1378-93. doi: 10.1158/2159-8290.CD-13-0005. Epub 2013 Oct 8. Cancer Discov. 2013. PMID: 24104062 Free PMC article.
Gauging the Long-Term Benefits of Ipilimumab in Melanoma.
Ribas A, Flaherty KT. Ribas A, et al. Among authors: flaherty kt. J Clin Oncol. 2015 Jun 10;33(17):1865-6. doi: 10.1200/JCO.2014.59.5041. Epub 2015 Feb 9. J Clin Oncol. 2015. PMID: 25667273 No abstract available.
sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.
Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH 3rd, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH 3rd, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. Kaur A, et al. Among authors: flaherty kt. Nature. 2016 Apr 14;532(7598):250-4. doi: 10.1038/nature17392. Epub 2016 Apr 4. Nature. 2016. PMID: 27042933 Free PMC article.
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.
Lu H, Liu S, Zhang G, Bin Wu, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W. Lu H, et al. Among authors: flaherty kt. Nature. 2017 Oct 5;550(7674):133-136. doi: 10.1038/nature24040. Epub 2017 Sep 27. Nature. 2017. PMID: 28953887 Free PMC article.
487 results